Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Case Rep Ophthalmol ; 12(2): 519-524, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34248585

RESUMO

An otherwise healthy 72-year-old Chinese patient diagnosed with exudative age-related macular degeneration and decreased vision in left eye was fully investigated. The retrospective analysis of past multimodal imaging revealed bilateral severe choroidal neovascularization and choroiditis associated with a positive tuberculin skin testing and interferon-gamma release assay (QuantiFERON-TB Gold - Cellestis®, Chadstone, VIC, Australia) suggestive of latent ocular tuberculosis. The variable presentation and tests' results interpretation represent the greatest limitations in understanding and treating intraocular TB (IOTB). This may present without any other systemic symptoms, the intraocular tissues are of limited access to biopsies and other tests, including imaging and immunological tests, are of relative value. This case highlights how variable may be the presentation of IOTB, which can be easily misdiagnosed leading to a delayed treatment and worse prognosis.

2.
J Rheumatol ; 35(5): 930-2, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18464316

RESUMO

An Italian Olympic athlete with a severe form of Behçet's disease was given infliximab. He had oral aphthosis, papulopustular and follicular lesions, and a bilateral cystoid macular edema. After the first 3 infusions, the mucocutaneous lesions disappeared and cystoid macular edema was much improved. Cyclosporine was stopped and the prednisone dose was progressively tapered until the cystoid macular edema disappeared.


Assuntos
Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Síndrome de Behçet/tratamento farmacológico , Adulto , Síndrome de Behçet/diagnóstico , Humanos , Infliximab , Masculino , Indução de Remissão/métodos , Esportes , Resultado do Tratamento , Fator de Necrose Tumoral alfa/antagonistas & inibidores
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA